Table 1.
Baseline characteristics
| Characteristic | Value (n=19) |
|---|---|
| Age (yr) | 70 (32–84) |
| Sex (female/male) | 13 (68)/6 (32) |
| Never smokers | 16 (84) |
| WHO performance statusa) | |
| 0/1/2 | 1(5)/16 (84)/2 (11) |
| Histology, adenocarcinoma | 19 (100) |
| Stage IV (by 8th TNM) | 19 (100) |
| Within the thoracic cavity (M1a) | 1 (5) |
| Single extrathoracic metastasisb) (M1b) | 3 (16) |
| Multiple extrathoracic metastases (M1c) | 15 (79) |
| Brain metastasis | 15 (79) |
| Leptomeningeal metastasis | 1 (5) |
| Brain RT before start of osimertinib | 7 (37) |
| No preceding brain RT (reasons) | 8 (42) |
| Small lesion | 6 |
| Old age with poor performance | 2 |
| Asymptomatic | 2 |
| Line of treatment, 1st | 19 (100) |
| Type of EGFR mutationc) | |
| ex19del | 11 (58) |
| L858R/L861Q | 7 (37) |
| G719A | 1 (5) |
Values are presented as median (range) or number (%). EGFR, epidermal growth factor receptor; RT, radiotherapy.
A World Health Organization (WHO) performance status of 0 indicates that the patient is fully active and able to carry out all normal activities without restrictions. A WHO performance status of 1 indicates that the patient is restricted in physically strenuous activity, but is ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work. A WHO performance status of 2 indicates that the patient is ambulatory and capable of all self-care, but unable to carry out any work activities for more than 50% of waking hours,
All cases were brain metastases,
Results of the tissue-based test at diagnosis.